Marc Beer, Chief Executive Officer, Chairman, and Co-founder for Renovia Inc, is an expert manager who boasts over 25 years of experience in both commercialization and development in the medical industry. He has overseen the production of products in the pharmaceutical, biotechnology, diagnostic, and device markets of U.S. medical products. Beer also serves as CEO of ViaCell, a specialist biotechnology firm focused on the preservation, collection, and development of umbilical cord stem cells. Marc Beer joined the company back in 2000. Since his involvement, the company has expanded to over 300 employees.
In addition to ViaCell and Renovia, Marc Beer is also the founding chairman for the directors’ board of GSGCC, which stands for Good Star Genetics Compensation Committee. He holds the title of founding chairman for the Minerva Neurosciences Inc Audit Committee, or MNIAC. Beer is also a member of the BAC, or Business Advisory Council at Miami University as well the Graduate Studies Research, or GSR, of Notre Dame. Basically, Beer is a big deal in medical circles. Now he is making a splash in the area of women’s health.
Recently, Marc Beer raised over $42 million dollars through Renovia for the development of both diagnostic and therapeutic products that treat pelvic floor disorders. Pelvic floor disorders occur when the “hammock” that holds pelvic organs weakens. The results of such a condition lead to urinary incontinence and fecal incontinence. For those at home, this means people develop weak bowels and cannot control their excretions. Urinary incontinence is estimated to affect 250 million women globally. Renovia’s first productfocused on pelvic floor disorders, titled Leva, recently gained FDA approval back in April.
A good part of the funding came from the Longwood Fund, which is a healthcare-focused investment firm. Altogether the $42 million will pay for the development of four additional diagnostic and therapeutic products aimed at pelvic floor disorders. Essentially, it is the next phase in the Leva device. The funding will also pay for initial trials of the drugs as well. Beer has high hopes for the investment and recently discussed his view in a public statement.
“It is a thrill to have support from healthcare investment leaders in the treatment of the millions of women affected by pelvic floor disorders,” Beer stated. “Together we share a vision of better diagnoses, treatment, and improvement for the millions of women who have pelvic floor disorders.” Renovia will use a digital health platform run off of sensor technology to create new treatment options for female pelvic floor disorders. Hopefully, the next generation of Leva will better equip healthcare providers with solutions to pelvic floor disorders, while lowering the associated long-term healthcare cost that is usually attached. Learn more: https://www.slideshare.net/MarcBeer